Table 1.

Cases who achieved complete response for more than 2 years in the literature

	Case 1	Case 2	Case 3	Case 4	Present case
Reported year [reference]	2011 [8]	2011 [8]	2013 [9]	2013 [10]	2014
Age/sex	70/male	69/male	71/male	74/male	83/male
Background liver disease	Hepatitis C	Hepatitis C	Hepatitis C	Hepatitis B	Non-viral, non-alcoholic
Tumor status at sorafenib initiation
Number	Single	Not described	Multiple	Single	-
Location	Not described	Three hepatic lesions	Segment IV and VII	Posterior segment	Right lobe
Maximum size	6 × 5 cm	Not described	9 cm	8.6 × 5.7 cm	-
Extension	Vascular invasion	Portal vein thrombosis	Portal vein thrombosis	Vertebral metastasis	Lung metastasis
Pathological diagnosis	None (based on the computed tomography image)	None (based on the computed tomography image)	Poorly/moderately differentiated hepatocellular carcinoma	Moderately differentiated hepatocellular carcinoma	Poorly differentiated hepatocellular carcinoma
Pretreatment before sorafenib	None	Not described	Synchro-level, Vitamin E	TACE → PEIT, RFA	TACE + RFA → HAIC (5-FU + CDDP)
Doses of sorafenib (period)
Initial dose	Not described	800 mg/day (10 days)	800 mg/day (2 months)	800 mg/day (2 weeks)	400 mg/day (1 month)
Second dose	→ 400 mg/day (55 months)	→ 400 mg/day (3 months)	→ 400 mg/day (18 months)	→ 400 mg/day (60 months)	→ 200 mg/day (1 months)
Third dose		→ 400 mg/2 days (57 months)			→ 800 mg/day (4 months)
Fourth dose					→ 400 mg/day (2 months)
Last doses					→ 200 → 100 → 200 mg/day (34 months)
Total period of sorafenib	60 months	62 months	20 months	60 months	42 months
Period of complete response	<27 months	38 months	28 months	54 months	34 months
Reported status	Alive	Alive	Alive	Alive	Alive

TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation; PEIT, percutaneous ethanol injection therapy; HAIC, hepatic arterial infusion chemotherapy; 5-FU, 5-fluorouracil; CDDP, cisplatin.